# S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

> **NCT00041132** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 56 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin
- **DRUG:** leucovorin
- **DRUG:** methotrexate
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT00041132
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2007-11
- **Final completion:** 2011-06
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041132, "S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00041132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*